Subject(s)
Adenocarcinoma/diagnostic imaging , Adenocarcinoma/secondary , Choline/analogs & derivatives , Fluorine Radioisotopes , Multimodal Imaging , Positron-Emission Tomography , Prostatic Neoplasms/pathology , Tomography, X-Ray Computed , Aged , Clavicle , Humans , Lymphatic Metastasis/diagnostic imaging , MaleABSTRACT
Although FDG PET and PET/CT have a well established role in the management of most cancer patients, they also have some limitations. For the last 15-20 years a growing number of non-FDG PET tracers have been used in research. Many of these new PET tracers are being investigated for the non-invasive assessment of different biologic functions in cancer cells. This unique information should contribute to making personalized cancer therapy a reality. This paper reviews the non-FDG PET tracers that are most likely to find clinical application, some of them in the near future.
Subject(s)
Fluorodeoxyglucose F18 , Multimodal Imaging/methods , Neoplasms/diagnostic imaging , Positron-Emission Tomography , Radiopharmaceuticals , Tomography, X-Ray Computed , Humans , Multimodal Imaging/trendsABSTRACT
Although FDG PET and PET/CT have a well established role in the management of most cancer patients, they also have some limitations. For the last 15-20 years a growing number of non-FDG PET tracers have been used in research. Many of these new PET tracers are being investigated for the non-invasive assessment of different biologic functions in cancer cells. This unique information should contribute to making personalized cancer therapy a reality. This paper reviews the non-FDG PET tracers that are most likely to find clinical application, some of them in the near future (AU)
